Progressive Supranuclear Palsy - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Progressive Supranuclear Palsy - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Progressive Supranuclear Palsy - Pipeline Review, H2 2015', provides an overview of the Progressive Supranuclear Palsy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Progressive Supranuclear Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Progressive Supranuclear Palsy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Progressive Supranuclear Palsy
 and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Progressive Supranuclear Palsy
 products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Progressive Supranuclear Palsy
 pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy
 pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Progressive Supranuclear Palsy Overview 7
Therapeutics Development 8
Pipeline Products for Progressive Supranuclear Palsy - Overview 8
Pipeline Products for Progressive Supranuclear Palsy - Comparative Analysis 9
Progressive Supranuclear Palsy - Therapeutics under Development by Companies 10
Progressive Supranuclear Palsy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Progressive Supranuclear Palsy - Products under Development by Companies 13
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 14
AB Science 14
AlzProtect SAS 15
Bristol-Myers Squibb Company 16
Prana Biotechnology Limited 17
ProteoTech, Inc. 18
Sellas Inc. 19
TauRx Therapeutics Ltd. 20
Progressive Supranuclear Palsy - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ASN-561 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AZP-2006 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BMS-986168 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DC-TAB - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DP-C016 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
masitinib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PBT-434 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PTI-51CH3 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PTI-51CH3 Backup - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
TPI-287 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TRx-0237 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
zolpidem tartrate - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Progressive Supranuclear Palsy - Recent Pipeline Updates 47
Progressive Supranuclear Palsy - Dormant Projects 58
Progressive Supranuclear Palsy - Dormant Projects 58
Progressive Supranuclear Palsy - Product Development Milestones 59
Featured News & Press Releases 59
Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases 59
Dec 10, 2013: Potential Treatment for Parkinson's & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights 59
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, H2 2015 8
Number of Products under Development for Progressive Supranuclear Palsy - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Progressive Supranuclear Palsy - Pipeline by AB Science, H2 2015 14
Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H2 2015 15
Progressive Supranuclear Palsy - Pipeline by Bristol-Myers Squibb Company, H2 2015 16
Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Limited, H2 2015 17
Progressive Supranuclear Palsy - Pipeline by ProteoTech, Inc., H2 2015 18
Progressive Supranuclear Palsy - Pipeline by Sellas Inc., H2 2015 19
Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd., H2 2015 20
Assessment by Monotherapy Products, H2 2015 21
Number of Products by Stage and Target, H2 2015 23
Number of Products by Stage and Mechanism of Action, H2 2015 25
Number of Products by Stage and Route of Administration, H2 2015 27
Number of Products by Stage and Molecule Type, H2 2015 29
Progressive Supranuclear Palsy Therapeutics - Recent Pipeline Updates, H2 2015 47
Progressive Supranuclear Palsy - Dormant Projects, H2 2015 58